Lantern Pharma's LP-184 Trial Shows Positive Results in Advanced Cancers

Encouraging Clinical Data for LP-184

• 🧬 LP-184, a next-generation synthetic-lethal drug candidate, has demonstrated meaningful clinical activity in a Phase 1A trial for advanced solid tumors.
• 🎯 The trial showed durable disease control in heavily pre-treated patients who had limited treatment options.
• 📈 Results included prolonged stable disease and tumor reduction across several biomarker-selected groups.

Favorable Safety Profile and Next Steps

• ✅ The safety profile of LP-184 remains strong and manageable, with no new safety signals reported.
• 🚀 Based on these positive outcomes, Lantern Pharma is advancing LP-184 into multiple Phase 1B/2 trials.
• 🎯 These trials will be guided by precision oncology biomarkers and will focus on high-need cancer indications such as pancreatic cancer, glioblastoma, and DNA damage repair–deficient solid tumors.

AI-Driven Drug Development Mission

• 🤖 Lantern Pharma is integrating AI and machine learning with precision oncology to accelerate drug development.
• 💡 This approach aims to target cancers with urgent unmet needs more effectively.